nephrolithiasis on indinavir.

NLM AIDSLINE Nephrolithiasis on indinavir.
December 30, 1999

Prescrire Int. 1999 Feb;8(39):22. Unique Identifier : AIDSLINE (1) Nephrolithiasis is found in 4-13% of patients treated with indinavir, an HIV protease inhibitor. Most of these stones are composed of indinavir. (2) Outcome is often favourable, with simple passage of the stone, but endoscopic or surgical treatment is sometimes required. (3) Crystalluria seems to be more frequent, but is often asymptomatic. (4) Prevention is based on fluid intake of at least 1.5 litres a day. Indinavir withdrawal may be necessary. JOURNAL ARTICLE HIV Protease Inhibitors/ADVERSE EFFECTS Human Indinavir/ADVERSE EFFECTS *Kidney Calculi/CHEMISTRY/EPIDEMIOLOGY/PREVENTION & CONTROL/ THERAPY Treatment Outcome

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Photographs from A Day with HIV Now Online Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 OHIO: Phila Health Department HIV Testing Well-Received CONNECTICUT: City's Circle Care Center is a Model for HIV Prevention UNITED STATES: New Compound Excels at Killing Persistent and Drug-Resistant Tuberculosis INDIA: India Faces TB Drug Shortage, Warns International Medical Org ALASKA: After Topping List for Chlamydia Rates, Alaska Seeing Some Improvement Tanzania: Police Abuse, Torture, Impede HIV Services Growing HIV/AIDS awareness in Indonesia's Papua region South Africa: Catastrophe as Eastern Cape drug stock-outs continue Community-led programmes critical to progress on AIDS in Sri Lanka One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs Ritonavir or indinavir - makes little difference Hydroxyurea-ddI-indinavir before antibodies Indinavir Penetration Enhanced After Addition of Low-Dose Ritonavir AIDS Therapies: Abacavir Equivalent To Indinavir For Patients With Moderate Viral Loads AIDS Therapies: Indinavir Impairs Early Adipocyte Differentiation AIDS Therapies: Indinavir-Ritonavir Treatment May Cause Ingrown Toenails HIV/AIDS: Indinavir/ritonavir less effective than lopinavir/ritonavir as first-line HAART HIV/AIDS Adverse Drug Reaction: Indinavir decreases nitric oxide production in HIV/AIDS patients Conference Coverage (ICAAC): Indinavir Sulfate Plus AZT Equals Sustained Decline in HIV Conference Coverage (ACTG): Best Combination So Far: Indinavir + AZT + ddI
Information in this article was accurate in December 30, 1999. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.